Valuation: Cerus Corporation

Market Cap 605M 530M 492M 452M 852M 58.39B 865M 5.86B 2.3B 28.57B 2.27B 2.22B 98.7B P/E 2026 *
-90.6x
P/E 2027 * -907x
Enterprise Value 605M 530M 492M 452M 852M 58.39B 865M 5.86B 2.3B 28.57B 2.27B 2.22B 98.7B EV / Sales 2026 *
2.54x
EV / Sales 2027 * 2.33x
Free-Float
96.31%
Yield 2026 *
-
Yield 2027 * -
1 day-3.21%
1 week-5.03%
Current month+3.42%
1 month+16.15%
3 months+55.67%
6 months+15.27%
Current year+46.60%
1 week 3.01
Extreme 3.01
3.25
1 month 2.56
Extreme 2.56
3.47
Current year 1.62
Extreme 1.62
3.47
1 year 1.15
Extreme 1.15
3.47
3 years 1.12
Extreme 1.12
3.47
5 years 1.12
Extreme 1.12
8.06
10 years 1.12
Extreme 1.12
8.87
Manager TitleAgeSince
Chief Executive Officer 51 2026-06-30
Chief Tech/Sci/R&D Officer 82 2015-06-30
Director of Finance/CFO 54 2009-05-03
Director TitleAgeSince
Director/Board Member 67 2019-03-03
Chairman 59 2026-03-15
Director/Board Member 72 2014-03-23
Date Insider Type Main position Quantity % Market Cap.
7/16/26 Sell

Chief Executive Officer

-16,666 0.0083%
7/1/26 Free

Chief Executive Officer

924,215 0.4613%
6/30/26 Free

Chief Financial Officer

-97,276 0.0485%
Change 5-day change 1-year change 3-year change Capi.($)
-3.21%-5.03%+111.19%+4.86% 625M
-1.70%-2.28%-21.74%+4.62% 121B
-0.49%-2.78%-1.63%-7.02% 12.65B
-0.15%-2.54%+58.63%+104.19% 8.99B
+8.70%+15.33%-41.19%-66.00% 4.46B
-1.11%-9.10%+0.60%+39.57% 2.68B
-0.70%-1.80%-8.42%-21.88% 1.65B
+0.89%-7.06%-23.89%-32.36% 1.59B
-2.03%+3.75%-2.53%-59.29% 1.56B
Average +0.02%-1.33%+7.89%-3.70% 17.2B
Weighted average by Cap. -1.17%-1.87%-14.75%+6.71%

Financials

2026 *2027 *
Net sales 238M 209M 194M 178M 335M 22.98B 340M 2.31B 903M 11.24B 894M 875M 38.84B 260M 228M 211M 194M 366M 25.07B 371M 2.52B 985M 12.27B 975M 954M 42.38B
Net income -6.24M -5.47M -5.07M -4.66M -8.79M -602M -8.91M -60.44M -23.66M -295M -23.42M -22.91M -1.02B -479K -420K -390K -358K -675K -46.25M -685K -4.64M -1.82M -22.63M -1.8M -1.76M -78.18M
Net Debt - -
Logo Cerus Corporation
Cerus Corporation is a biomedical products company. The Company is focused on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT Blood System, which is based on its proprietary technology for controlling biological replication, is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. Its INTERCEPT Blood System is intended for use with blood components and certain of their derivatives: platelets, plasma, red blood cells and to produce INTERCEPT Fibrinogen Complex (IFC), and pathogen reduced plasma, cryoprecipitate reduced. The INTERCEPT Blood System for Cryoprecipitation uses its plasma system to produce IFC for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. In addition, the INTERCEPT Blood System for Cryoprecipitation is used to produce pathogen reduced plasma, cryoprecipitate reduced.
Employees
268
Date Price Change Volume
26-07-22 US$3.020 -3.21% 2,186,376
26-07-21 US$3.120 -0.95% 2,849,612
26-07-20 US$3.150 +0.64% 1,921,525
26-07-17 US$3.130 -2.49% 2,428,479
26-07-16 US$3.210 +0.94% 1,852,870
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
3.020USD
Average target price
4.667USD
Spread / Average Target
+54.53%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CERS Stock